2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2752 Low-count monoclonal B-cell lymphocytosis (MBL) and risk of acute venous thromboembolism

George A Cholack, MD, MSc, Sameer A. Parikh, MBBS2, Sara J Achenbach3, Amber B Koehler, PA-C4, Bradley R Salonen, MD5, Dennis P. Robinson6, Aaron Norman7, Kari G Rabe, MS8, Yuan Yao, MD, MS9, Nicholas J Boddicker, PhD10, Celine Vachon, PhD11, Janet E Olson, PhD12, Lindsey Elizabeth Roeker, MD13, Timothy Call, MD14, Paul J. Hampel, MD15, Yucai Wang, MD, PhD16, James R. Cerhan, MD, PhD17, Aneel Ashrani, MD, MS18, Curtis A. Hanson, MD19, Tait D Shanafelt, MD20, Susan L. Slager, PhD21
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Stanford University, Stanford, California, United States
21 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States

Introduction: Chronic lymphocytic leukemia (CLL) is an established risk factor for venous thromboembolism (VTE), with ~6-fold increased risk relative to the general population (Koehler et al. J Thromb Haemost, 2025). Monoclonal B-cell lymphocytosis (MBL) affects roughly 8-10 million adults >40 years old in the United States. MBL is classified into two immunophenotypes: CLL-type MBL (co-expression of CD5, CD23, and CD20) and non-CLL-type MBL (absence of CD5). CLL-type MBL, the precursor state to CLL, is further subdivided into high-count (HC)-MBL (clonal B-cell count >0.5x109/L) and low-count (LC)-MBL (clonal B-cell count <0.5x109/L), the latter being the most prevalent form of MBL. It is currently unknown if individuals with LC-MBL have similar increased risk of VTE. Given the high prevalence of LC-MBL, even modest increases in VTE risk, if present, could have substantial population-level implications. Herein, we utilized the largest cohort of individuals systematically screened for MBL to date to evaluate the association between MBL and incident acute VTE.

Methods: Participants were from the Mayo Clinic MBL Biobank, which includes ~10,500 adults age ≥40 years who had no prior history of hematologic malignancy and were systematically screened for MBL using eight-color flow cytometry. The present analysis included 8,064 participants residing within the 27-county region of southern Minnesota and western Wisconsin surrounding Mayo Clinic in Rochester, Minnesota, where comprehensive medical records were available to ascertain acute VTE. Radiographically confirmed acute VTE following screening was identified by ICD codes and confirmed by medical record review. Events included deep vein thrombosis (DVT) and pulmonary embolism (PE). Cumulative incidence accounting for competing risks of death was estimated, and Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for age and sex. We further adjusted for established VTE risk factors including comorbidity burden (Charlson Comorbidity Index ≥1 vs 0), smoking status (ever vs never), history of solid tumors, and either reported history of VTE or a 297-variant polygenic risk score (PRS) for VTE (Klarin et al. Nat Genet, 2019). As an external validation of the VTE-PRS, we report the effect estimate for the top 5% versus the lower 95% of this PRS.

Results: Among 8,064 individuals, 1,214 (15.1%) had CLL-type MBL (96.4% LC-MBL), and 199 (2.5%) had non-CLL-type MBL. The median ages in years of individuals were as follows: 71.9 (CLL-type MBL), 78.4 (non-CLL-type MBL), 65.4 (no MBL). Across all subgroups, the majority were non-Hispanic White (95.7%), non-smokers (62.1%), and had no prior history of VTE within 5 years of MBL screening (97.7%). Compared with individuals with LC-MBL, individuals with HC-MBL (N=44) were older (median 74.3 vs. 71.8 years) and more likely male (70.5% vs 47.1%), but were otherwise similar. With current median follow-up of 6.1 years, only 2 of 1,170 individuals with LC-MBL progressed to CLL. The 5-year cumulative incidence of CLL (2008 criteria) was 0%.

With current follow-up, 306 individuals developed acute VTE (56 CLL-type MBL, 6 non-CLL-type MBL, and 244 no MBL). The first VTE event after screening included 156 (51.0%) individuals with PE, 139 (45.4%) with lower extremity DVTs, and 11 (3.6%) with upper extremity DVTs. The 5-year cumulative VTE incidence was 2.6% in individuals without MBL, 2.8% with CLL-type MBL, and 1.1% with non-CLL-type MBL, with no statistically significant differences across groups. Compared to no MBL, neither CLL-type (HR=1.12, 95%CI: 0.83-1.51) nor non-CLL-type MBL (HR=0.66, 95%CI: 0.29-1.49) was associated with acute VTE. Similar effect sizes were observed when analysis of CLL-type MBL was restricted to LC-MBL (HR=1.13, 95%CI: 0.84-1.53) or HC-MBL (HR=0.95, 95%CI 0.24-3.85). All results held after further adjustment for the previously described VTE risk factors, including the PRS for VTE. Participants in the highest 5% of the PRS had an increased risk of VTE (HR 2.23, 95%CI 1.54-3.24), adjusting for age and sex.

Conclusions: In contrast to numerous studies showing increased VTE risk in CLL, we found no evidence of increased acute VTE risk among individuals with LC-MBL. This suggests that the increased risk of VTE arises later in the MBL-to-CLL disease continuum rather than during the earlier LC-MBL stage. Increased VTE surveillance is unlikely to be warranted in individuals with LC-MBL.
George A Cholack, MD, MSc: No relevant conflicts of interest to declare.